ABBOTT RESEARCHERS FIND RARE GROUP OF PEOPLE WITH CONTROLLED HIV WHO COULD BE A KEY TO UNLOCKING CURE

- Study of more than 10,000 people identifies a rare group with controlled HIV in the Democratic Republic of Congo, suggesting additional research could uncover links between natural virus suppression and future treatments

- Discovery is a result of Abbott's continued virus hunting efforts, which also uncovered a new strain of HIV in 2019

- Abbott's decades of work in global viral surveillance has advanced the understanding of HIV and allowed the company to quickly respond to the COVID-19 pandemic with its diagnostic tests

ABBOTT PARK, Ill., March 2, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that a team of scientists has found an unusually high number of people in the Democratic Republic of Congo (DRC) who test positive for HIV antibodies, but have low to non-detectable viral load counts – without the use of antiretroviral treatment. These people are referred to as HIV elite controllers. These groundbreaking findings published today in EBioMedicine (part of The Lancet), may help researchers uncover biological trends within this population that could lead to advancements in HIV treatments - and potentially vaccines.

Researchers from Abbott, the Johns Hopkins University, the National Institute of Allergy and Infectious Diseases, the University of Missouri-Kansas City and the Université Protestante au Congo found that the prevalence of HIV elite controllers was 2.7-4.3% in the DRC - compared to a 0.1-2% prevalence worldwide. This new research will fuel additional studies that look to understand this unique immune response. Findings from the study could lead researchers closer to their goal of ending the HIV epidemic by uncovering links between natural virus suppression and future treatments.

"The finding of a large group of HIV elite controllers in the DRC is significant considering that HIV is a life-long, chronic condition that typically progresses over time," said Tom Quinn, M.D., director of Johns Hopkins Center for Global Health, and chief of the International HIV/AIDS Research Section of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and one of the study authors. "There have been rare instances of the infection not progressing in individuals prior to this study, but this high frequency is unusual and suggests there is something interesting happening at a physiological level in the DRC that's not random."

Since the beginning of the global HIV epidemic, 76 million people have been infected with HIV and 38 million people today are living with the virus. As the first company to develop an FDA-approved test for HIV more than 30 years ago, Abbott understands the importance of HIV research and established its Global Viral Surveillance Program to identify HIV and hepatitis mutations – ensuring its diagnostic tests remain up to date. With the origins of the HIV epidemic traced to sub-Saharan Africa, specifically the DRC, this region is of specific interest to the scientific community. These new findings from Abbott researchers and partners are a continuation of virus hunting efforts that led to the identification of a new strain of HIV in 2019.

"Global surveillance work keeps us ahead of emerging infectious diseases - and in this instance we realized we had found something that could be another step toward unlocking a cure for HIV," said Michael Berg, Ph.D., an associate research fellow in infectious disease research at Abbott, and lead author of the study. "The global research community has more work to do – but harnessing what we learn from this study and sharing it with other researchers puts us closer to new treatments that could possibly eliminate HIV."

Plasma samples from surveillance efforts collected in 1987, 2001-03 and 2017-19 in the DRC – home to the oldest known HIV strains – allowed researchers to rule out false positives, collection site bias, high genetic diversity and antiretroviral treatment as the cause of non-detectable viral counts in 10,457 patients from 2017 to 2019. Abbott’s ARCHITECT® HIV Ag/Ab Combo tests and m 2000™ RealTi m e HIV-1 tests were used in the study to detect HIV antibodies and viral load ranges, respectively, in participants.

"Every new HIV discovery is another piece in the evolutionary jigsaw puzzle that we're trying to understand," said Carole McArthur, Ph.D., M.D., professor in the department of oral and craniofacial sciences, University of Missouri-Kansas City, director of residency research in pathology, Truman Medical Center, and one of the study authors. "Each of these pieces helps us see a bit more clearly as to where we need to look next and contributes to the knowledge bank that all researchers will turn to in the next phase of our work."

More than 25 years of hunting viruses across the globe

As a leader in blood screening and infectious disease testing, Abbott created its Global Viral Surveillance Program more than 25 years ago to monitor HIV and hepatitis viruses and identify mutations, which helps ensure the company's diagnostic tests remain up to date. The surveillance program continues to be a pathway fueled by collaboration, enabling researchers to proactively evaluate and solve infectious disease challenges.

Abbott's surveillance and emerging virus discovery work allowed the company to quickly respond to the COVID-
19 pandemic. Abbott will increase its efforts to identify, track and prevent future pandemics across many different types of infectious diseases.

To learn more about Abbott’s virus hunting efforts, visit www.abbott.com/virushunters.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

1 A high prevalence of potential HIV elite controllers identified over 30 years in Democratic Republic of Congo, EBioMedicine.


SOURCE Abbott
For further information: Media, Kim Modory, 224-668-4696; Darcy Ross, 224-667-3655; For all other countries, see: https://www.abbott.com/corpnewsroom/utilities/media-contacts.html; Financial, Laura Dauer, 224-667-2299

Additional assets available online: PHOTOS